SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 8.8% – Still a Buy?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) traded up 8.8% during trading on Thursday . The company traded as high as $14.76 and last traded at $14.9390. Approximately 1,091,829 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 8,193,203 shares. The stock had previously closed at $13.73.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on SLS. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Friday, July 17th. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Stock Performance

The firm has a market capitalization of $3.10 billion, a P/E ratio of -72.76 and a beta of 2.48. The company has a 50-day moving average price of $12.23 and a 200-day moving average price of $7.97.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

Institutional Trading of SELLAS Life Sciences Group

A number of institutional investors and hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System boosted its stake in SELLAS Life Sciences Group by 31,891.4% during the 2nd quarter. California State Teachers Retirement System now owns 2,987,040 shares of the company’s stock worth $44,089,000 after acquiring an additional 2,977,703 shares during the last quarter. Marshall Wace LLP increased its stake in SELLAS Life Sciences Group by 23,550.0% in the second quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock valued at $5,947,000 after purchasing an additional 2,704,007 shares in the last quarter. Geode Capital Management LLC raised its holdings in SELLAS Life Sciences Group by 168.2% in the second quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock worth $4,819,000 after purchasing an additional 1,379,988 shares during the period. Millennium Management LLC raised its holdings in SELLAS Life Sciences Group by 341.0% in the fourth quarter. Millennium Management LLC now owns 1,387,849 shares of the company’s stock worth $5,232,000 after purchasing an additional 1,073,147 shares during the period. Finally, State Street Corp raised its holdings in SELLAS Life Sciences Group by 60.8% in the fourth quarter. State Street Corp now owns 2,188,171 shares of the company’s stock worth $8,249,000 after purchasing an additional 827,257 shares during the period. 17.38% of the stock is owned by institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.